drugset / Trial / NCT07471932
A Study of LAD106 in Healthy Adult Participants
RandomizedSequentialTriple-blindTreatment
Summary
The main aim of this study is to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and pharmacodynamics (PD) of single ascending doses of LAD106 (Part A) and multiple ascending doses of LAD106 (Part B) in human healthy participants.
Timeline
- Start
- 2026-02-17
- Primary completion
- 2027-05-31
- Completion
- 2027-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LAD106 | Unknown | — | — |
| Comparator | Lebrikizumab | Monoclonal antibody | — | — |
Indications
No indication recorded.